Literature DB >> 8932330

Photodynamic therapy using intravenous delta-aminolaevulinic acid-induced protoporphyrin IX sensitisation in experimental hepatic tumours in rats.

K Svanberg1, D L Liu, I Wang, S Andersson-Engels, U Stenram, S Svanberg.   

Abstract

The efficacy of photodynamic therapy (PDT) using delta-aminolaevulinic acid (ALA)-induced protoporphyrin IX (PpIX) sensitisation and laser light at 635 nm was investigated in the treatment of experimental hepatic tumours. The model of liver tumours was induced either by local inoculation or by administration of tumour cells through the portal vein in rats. ALA at a dose of 60 mg kg(-1) b.w. was intravenously administered 60 min before PDT. PpIX accumulation in tumour, normal liver and abdominal wall muscle was detected by means of laser-induced fluorescence (LIF). Laser Doppler imaging (LDI) was used to determine changes in the superficial blood flow in connection with PDT. Histopathological examinations were performed to evaluate the PDT effects on the tumour and the surrounding liver tissue, including pathological features in the microvascular system. The accumulation of PpIX, as monitored by LIF, showed high fluorescence intensities at about 635 nm in both the hepatic tumour tissue and normal liver and low values in the abdominal wall. LDI demonstrated that the blood flow in the treated tumour and its surrounding normal liver tissue decreased immediately after the PDT, indicating an effect on the vascular system. A large number of thrombi in the irradiated tumour were found microscopically 3 h after the PDT. The tumour growth rate showed a marked decrease when evaluated 3 and 6 days after the treatment. These results show that the ALA-PDT is effective in the inhibition of growth of experimental hepatic tumours.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8932330      PMCID: PMC2074833          DOI: 10.1038/bjc.1996.584

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  42 in total

Review 1.  Hematoporphyrin and HPD: photophysics, photochemistry and phototherapy.

Authors:  D Kessel
Journal:  Photochem Photobiol       Date:  1984-06       Impact factor: 3.421

2.  Porphyrin-sensitized photoinactivation of human cells in vitro.

Authors:  J Moan; J V Johannessen; T Christensen; T Espevik; J B McGhie
Journal:  Am J Pathol       Date:  1982-11       Impact factor: 4.307

3.  Porphyrin metabolism in human neoplastic tissues.

Authors:  G F Rubino; L Rasetti
Journal:  Panminerva Med       Date:  1966 Jul-Aug       Impact factor: 5.197

4.  Determination of [3H]- and [14C]hematoporphyrin derivative distribution in malignant and normal tissue.

Authors:  C J Gomer; T J Dougherty
Journal:  Cancer Res       Date:  1979-01       Impact factor: 12.701

5.  Blood flow in transplantable bladder tumors treated with hematoporphyrin derivative and light.

Authors:  S H Selman; M Kreimer-Birnbaum; J E Klaunig; P J Goldblatt; R W Keck; S L Britton
Journal:  Cancer Res       Date:  1984-05       Impact factor: 12.701

6.  Experimental laser phototherapy of the Morris 7777 hepatoma in the rat.

Authors:  S Holt; J Tulip; D Hamilton; J Cummins; A Fields; C Dick
Journal:  Hepatology       Date:  1985 Mar-Apr       Impact factor: 17.425

7.  Estimation of liver tumor volume using different formulas - an experimental study in rats.

Authors:  G Carlsson; B Gullberg; L Hafström
Journal:  J Cancer Res Clin Oncol       Date:  1983       Impact factor: 4.553

8.  Autoradiographic distribution of hematoporphyrin derivative in normal and tumor tissue of the mouse.

Authors:  P J Bugelski; C W Porter; T J Dougherty
Journal:  Cancer Res       Date:  1981-11       Impact factor: 12.701

9.  Differential interaction of porphyrins used in photoradiation therapy with ferrochelatase.

Authors:  H A Dailey; A Smith
Journal:  Biochem J       Date:  1984-10-15       Impact factor: 3.857

10.  Tumor destruction and kinetics of tumor cell death in two experimental mouse tumors following photodynamic therapy.

Authors:  B W Henderson; S M Waldow; T S Mang; W R Potter; P B Malone; T J Dougherty
Journal:  Cancer Res       Date:  1985-02       Impact factor: 12.701

View more
  7 in total

1.  Mechanisms in photodynamic therapy: part one-photosensitizers, photochemistry and cellular localization.

Authors:  Ana P Castano; Tatiana N Demidova; Michael R Hamblin
Journal:  Photodiagnosis Photodyn Ther       Date:  2004-12       Impact factor: 3.631

2.  Pk11195, a mitochondrial benzodiazepine receptor antagonist, reduces apoptosis threshold in Bcl-X(L) and Mcl-1 expressing human cholangiocarcinoma cells.

Authors:  A C Okaro; D A Fennell; M Corbo; B R Davidson; F E Cotter
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

Review 3.  Application of photodynamic therapy for liver malignancies.

Authors:  Heng Zou; Fusheng Wang; Jiang-Jiao Zhou; Xi Liu; Qing He; Cong Wang; Yan-Wen Zheng; Yu Wen; Li Xiong
Journal:  J Gastrointest Oncol       Date:  2020-04

4.  Effective treatment of liver metastases with photodynamic therapy, using the second-generation photosensitizer meta-tetra(hydroxyphenyl)chlorin (mTHPC), in a rat model.

Authors:  J P Rovers; A E Saarnak; A Molina; J J Schuitmaker; H J Sterenborg; O T Terpstra
Journal:  Br J Cancer       Date:  1999-10       Impact factor: 7.640

5.  Interstitial photodynamic therapy with the second-generation photosensitizer bacteriochlorin a in a rat model for liver metastases.

Authors:  J P Rovers; J J Schuitmaker; A L Vahrmeijer; J H van Dierendonck; O T Terpstra
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

6.  Selective accumulation of ALA-induced PpIX and photodynamic effect in chemically induced hepatocellular carcinoma.

Authors:  M Otake; M Nishiwaki; Y Kobayashi; S Baba; E Kohno; T Kawasaki; Y Fujise; H Nakamura
Journal:  Br J Cancer       Date:  2003-08-18       Impact factor: 7.640

7.  Enhanced effects of aminolaevulinic acid-based photodynamic therapy through local hyperthermia in rat tumours.

Authors:  D K Kelleher; J Bastian; O Thews; P Vaupel
Journal:  Br J Cancer       Date:  2003-07-21       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.